Designing new antimicrobial peptides to fight bacterial infections
Official title: Precision Design of Antimicrobial Peptides Against Bacterial Infections
Funded at Purdue University · NIH-10915026 · Data updated 2026-11-12
This study is working on creating new types of treatments called antimicrobial peptides to help fight infections caused by bacteria that don't respond to regular antibiotics, using smart technology to find the best options while keeping them safe for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | September 23, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $302,928 |
| NIH project number | 5R01GM143370-03 |
| Project ID | NIH-10915026 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on developing innovative antimicrobial peptides (AMPs) to combat antibiotic-resistant bacterial infections. By utilizing advanced techniques such as machine learning and peptide synthesis, the project aims to create effective and selective AMPs that target specific resistant pathogens while minimizing toxicity. The researchers are employing a generative adversarial network model to generate diverse AMP candidates, which will be tested for their antibacterial properties. This approach seeks to provide a new class of therapeutics that can complement existing antibiotics and address the growing challenge of antibiotic resistance.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for bacterial infections that are currently difficult to manage due to antibiotic resistance.
How similar studies have gone: Other research has shown promise in using antimicrobial peptides as effective treatments, indicating that this approach has potential for success.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Li, Jianing — Purdue University
- Study coordinator: Li, Jianing
Related research
Other NIH-funded projects on the same topics.
-
Host-Directed Orynotide for MDR Gram-Negative Infections
A new drug candidate called Orynotide MTD12813 is being developed to treat serious drug-resistant infections caused by bacteria like Acinetobacter and Enterobacteriaceae.
-
Genomic-informed, low-cost, portable test to rapidly identify drug-resistant bacterial infections
A portable, affordable test called BADLOCK could quickly identify bacteria and resistance genes from blood samples to help treat drug-resistant infections.
-
Novel BMX antibiotics for tough Gram-negative infections
A new class of BMX antibiotics is being developed to fight hard-to-treat Gram-negative infections like Acinetobacter baumannii in patients.
-
Center to speed up antibacterial drugs for hard-to-treat infections
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
PACC1 in the body’s defense against bacterial infections and sepsis
A study exploring how a protein called PACC1 helps immune cells fight bacteria and prevent sepsis, with potential benefits for people at risk of severe infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.